Ascendis Pharma A/S (FRA:A71)

Market Cap	11.19B
Revenue (ttm)	646.55M
Net Income (ttm)	-232.94M
Shares Out	n/a
EPS (ttm)	-3.87
PE Ratio	n/a
Forward PE	78.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	181.00
Previous Close	178.00
Day's Range	181.00 - 181.00
52-Week Range	115.00 - 186.00
Beta	n/a
RSI	51.74
Earnings Date	Feb 11, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 1,017
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A71

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.